With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity ...
NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and ...
Pfizer says COVID vaccine protection lasts at least 6 months; Company can now seek full FDA approval
The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said Thursday. The companies can now ...
Pfizer's vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in a late-stage clinical trial. The shot's protection declined from ...
With the endorsement, Abrysvo joins a formal roster of maternal vaccines the Centers for Disease Control and Prevention recommends before birth, such as those for whooping cough, influenza and ...
Pfizer Inc (NYSE:PFE) announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being developed for ...
Pfizer and BioNTech said Thursday that trials suggest their vaccine is effective against a coronavirus variant that first emerged in South Africa, which some experts worry might evade existing shots.
TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially ...
A single dose of Pfizer's vaccine was 77.8% effective against more severe lower respiratory tract illness with three or more symptoms through a second season, down from the 88.9% efficacy following ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results